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Title: Containment Matters: Set and Setting in Contemporary Psychedelic Psychiatry 
Abstract:  
Over the past decade and a half, psychedelic drug-induced experiences have been returning to 
psychiatry as promising new healing modalities. The case of psychedelic-assisted psychotherapy 
can inform how we think about the context of drug use because psychedelics are commonly 
considered to be sensitive to the ‘[mind]set and setting’ of their use. As such, epistemic and 
therapeutic concerns amongst psychedelic researchers and therapists over the importance of set 
and setting are interwoven. My ethnography of psychedelic therapeutics both inside and outside 
of the clinical trials on the east coast of the US from 2015-2019 suggests that there are added 
political and economic imperatives to contain psychedelic use. Working with this insight, I 
suggest psychedelic researchers and therapists are producing immense experiences that tend to 
overflow the attempts at their containment. I also identify two qualities central to the set and 
setting of the emerging modality of psychedelic-assisted psychotherapy. The first is a labor of 
protecting spaces which reveals an attentiveness to disconnection that can be read as in tension 
with the more commonly-evoked emphasis on connection found within psychedelic discourses. 
The second is how psychedelic experiences (as ‘mind-manifesting’) are understood to reflect the 
self, and in so doing re-present epistemic disagreements about the nature of the self thus 
reflected. Taken together, I propose that these two qualities of psychedelic containment offer an 
analytics for reading the contemporary cultural politics of psychedelic use. 
 
Keywords: protection, reflection, connection, leaks, overflows, context 
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In the end, it’s altered traits, not altered states, that matter. ‘By their fruits shall ye know 
them.’ It’s good to learn that volunteers having even this limited experience had lasting benefits. 
But human history suggests that without a social vessel to hold the wine of revelation, it tends to 
dribble away...That’s the next research question, it seems to me: What conditions of community 
and practice best help people to hold on to what comes to them in those moments of revelation, 
converting it into abiding light in their own lives?  
(Huston Smith, commenting on Griffiths et al., 2006) 
Introduction 
There is a current upswelling of excitement regarding psychedelic-assisted treatments for 
clinical targets (Steinhardt and Noorani, 2020), including treatment-resistant depression, anxiety, 
post-traumatic stress disorder, addiction and obsessive-compulsive disorder. Psychedelic 
research trials have been celebrated in recent years for producing lasting change, measured on 
certain axes: reduction in clinical symptoms, improved functioning and wellbeing, and for those 
partial to countercultural or ecological sensibilities, increases in scores of ‘nature-relatedness’ 
and ‘openness’ that are sustained for months or even years. The dominant explanation for how 
these research trials have produced these effects is through the inculcation of strong, affectively-
charged psychedelic experiences that generate a profusion of meaning, varying in content from 
early biographic memories to re-experiencing past lives, non-dual awareness and transformative 
insights and visions. 
Johns Hopkins University in Baltimore houses the pre-eminent US university research 
group studying psychedelics in what has come to be known as the ‘psychedelic renaissance’, 
publishing a landmark study in 2006 reporting that administration of the psychedelic compound 
psilocybin can occasion mystical-type experiences with lasting significance. From 2013 to 2015 
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I worked with the Johns Hopkins research team, conducting retrospective semi-structured 
interviews with participants from a psychedelic-assisted smoking cessation pilot trial. By then 
the university’s psychedelic research program was already well-established, having received 
regulatory approval for its first study in 2000. In 2008 Matthew Johnson, then an instructor, now 
a full professor, devised a pilot research trial to look into the role that psilocybin could play in 
helping people quit cigarettes. My own postdoctoral research sought to identify perceived 
mechanisms of change by which the trial participants’ psilocybin experiences helped them quit 
smoking. I conducted follow-up interviews in the ‘session room’ where participants had spent 
many hours under the influence of psychedelics on a sofa. Ostensibly to help jog their memories 
through context-recall, I found the delight with which former participants re-entered the session 
room, which for some was several years after their involvement in the trial, palpable. 
When framed as efficacious, well-contained and commodifiable treatments, psychedelic-
assisted therapies offer much promise for an emerging ‘psychedelic psychiatry’. The market 
agrees: at the time of writing, Compass Pathways, a UK-based for-profit company set up during 
my fieldwork to delivery psychedelic-assisted therapy for treatment-resistant depression received 
an initial valuation on the stock market of over five hundred million dollars. This article is 
informed by both my experiences at Johns Hopkins and a subsequent ethnography of the 
relations between the university-based psychedelic clinical trials and their imbrications with a 
broader, community-based array of psychedelics use in healing and self-exploration conducted 
between 2015 and 2019. My ethnography was conducted within what is called the ‘psychedelic 
community’, a term used by my interlocutors to designate a broad range of actors convening 
today at meet-ups and conferences mostly organized in US and western European cosmopolitan 
cities, to represent, share and celebrate overlapping interests and concerns with psychedelic 
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drugs and plant medicines including lysergic acid diethylamide (LSD), ‘magic’ mushrooms and 
their key psychoactive compound, psilocybin, the peyote cactus and its key psychoactive 
compound, mescaline, and the ayahuasca decoction and the psychoactive compound, N, N-
Dimethyltryptamine that it commonly contains. Actors in the psychedelic community include 
research scientists, underground researchers, ‘psychonauts’ (explorers of the mind) and 
psychedelic research aficionados, indigenous, shamanic and neo-shamanic healers, therapists and 
those seeking alternative modes of therapy, drug policy advocates, psychedelic festival and 
party-goers, hippies, Yippies, New Agers, academics, amateur botanists and mycologists, 
organizers of psychedelic societies and integration groups and, increasingly, entrepreneurs and 
pharmaceutical actors interested in the commodification of these substances.  
This article is based on research conducted largely in Baltimore and New York, though 
also the Bay area of the US’ west coast and London, from 2015-2019. It draws its data from 
approximately forty semi-structured interviews, and notes from ongoing conversations and 
participant observation with members of the psychedelic community. In part, my interviews 
sought to determine how my interlocutors understood the current revival of research into 
psychedelics and the nature and effects of psychedelic experiences. I also documented the 
movements of prototypical actors in the US who have shaped the recent revival of interest in 
psychedelic science. Increasingly I came to dwell on the recurrence of tropes amongst my 
interlocutors of ‘building containers’ and ‘holding spaces’, and in 2019 reread both my 
interviews and contemporary and historical scientific literature with these key themes in mind. 
My argument here focuses on the term ‘set and setting’, which is ubiquitous in the 
psychedelic community, highlighting the centrality of the context of psychedelic drug use for the 
nature of the experiences and effects engendered. I will argue that, today, the term co-articulates 
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not only epistemic and therapeutic but also political and economic imperatives to contain 
psychedelic experiences. This has been especially useful as a safeguard against concerns voiced 
over a repeat of the history of psychedelic prohibition that began in the 1960s. For instance 
Robert (“Bob”) Jesse, an authoritative voice within the contemporary US psychedelic 
community and kick-starting the Johns Hopkins psilocybin research with his behind-the-scenes 
work in the 1990s, explained at New York’s large psychedelics conference Horizons in 2016 that 
the pro-psychedelic audience will find the scientific research the easiest mode of psychedelic use 
to talk about, 
“with your next-door neighbor, your professors, the people you work with. Why? 
Because it gives the accurate appearance of being well-contained. The sessions are safeguarded. 
They’re conducted by trained people. The protocols are approved by institutional review boards 
and government regulators. The whole thing is contained, so that it doesn’t look like the drugs 
and the drug experiences are going to spill out into the streets. In other words, it’s made safe to 
talk about, and therefore easy to take in” (Jesse, 2016, original emphasis). 
Taking my cue from Jesse, and inspired by scholarship that investigates the materiality of 
containers, I draw on ethnographic examples to trace ways that psychedelic experiences leak and 
overflow beyond the circumscribed settings of their use. These excesses may index modes of 
therapeutic efficacy not captured by their scientific investigation through clinical trials. I then 
offer two qualities central to the set and setting of the emerging modality of psychedelic-assisted 
psychotherapy. The first is a labor of protecting spaces which reveals an attentiveness to 
disconnection that can be read as in tension with the more commonly-evoked emphasis on 
connection found within psychedelic discourses. The second is how psychedelic experiences (as 
‘mind-manifesting’) are understood to reflect the self, and in so doing re-present epistemic 
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disagreements about the nature of the self thus reflected. Taken together, I propose that these two 
qualities of psychedelic containment offer an analytics for reading the contemporary cultural 
politics of psychedelic use. By attending to the material-semiotic emphasis on containment that 
underlies the return of psychedelic research and therapeutics, my overall hope is to reveal its 
organizing role in shaping how many in the global North are coming to think about psychedelics 
not just therapeutically and epistemically but also politically and culturally. 
Set and setting 
The term ‘set and setting’ is pervasive in the psychedelic renaissance, continuous with the 
deep appreciation of many psychedelic researchers in the mid-twentieth century for the context 
of the use of psychedelics. Already of concern for clinical researchers working with LSD in the 
1950s, the term was coined by American academics-turned-countercultural gurus Timothy 
Leary, Ralph Metzner and Richard Alpert in 1964: 
“the nature of the experience depends almost entirely on [mind]set and setting. Set 
denotes the preparation of the individual, including his personality structure and his mood at the 
time. Setting is physical—the weather, the room’s atmosphere; social— feelings of persons 
present towards one another; and cultural—prevailing views as to what is real.” 
(Leary, Metzner and Alpert, 1964, p.9). 
In the context of today’s clinical trials with psychedelics, [mind]set is commonly 
understood as the prepared state of an individual mind, optimized in accordance with the limited 
flexibility afforded by relatively fixed personality traits. It is operationalized as the psychic 
setting of the psychedelic experience. In turn, setting in the clinical and basic science research 
has been mostly used to indicate the immediate physical surroundings for the psychedelic 
experience. Reference to set and setting has been a loud and persisting check on the fetishizing 
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of the drugs, offering an opposing pole to assuming all the effects of drugs come from the drugs 
themselves – a way of thinking Richard DeGrandpre (2006) has dubbed ‘pharmacologicalism’. 
Indeed, the above citation from Leary and his colleagues indicates the possibility of 
programming one’s psychedelic experience through controlling the set and setting,i raising the 
issue of replacing one kind of reductionism with another. In his recent analysis of set and setting 
in American Trip, Ido Hartogsohn outlines this reductionist bind and solves it with a thin 
universalism of what “the psychedelic experience” (in the singular) does: namely, an 
intensification of sensations and meaning, a hyperassociative mode of thinking and a blurring of 
boundaries. These universal or elementary features of psychedelics are then “altered, modified, 
inflected, and interpreted through their interactions with society and culture” (2020, p.20-21). 
Hartogsohn’s strategy of appealing to universals that are instantiated according to local social 
and cultural variations reinforces the original dichotomy between drug and context. In this article 
I refuse the bind altogether. Instead, I use ethnographic and historical data evidencing the force 
of the appeals to ‘set and setting’ (including the discursive effects of Hartogsohn’s own 
contribution) to articulate how use of the term shapes our understanding of psychedelics, and 
what in turn this might reveal for how we coproduce etic terms alongside the emic ones found in 
our fieldsites. 
The emphasis on set and setting speaks to the broader projects of the medical humanities 
and social sciences, where the roles of context and relationality in the commodification, 
distribution and use of drugs-as-medicines are foregrounded (for example, Whyte et al., 2002). 
Anthropologists Anita Hardon and Emilia Sanabria have called for an appreciation of the fluidity 
of drugs, arguing that what drugs are, as much as what they do, changes along with their context 
(Hardon and Sanabria, 2017). In relation to psychedelics, historian Matthew Oram has 
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challenged the dominant narrative that the excesses of the US counterculture in the 1960s caused 
psychedelic prohibitionism as a backlash by the Nixon administration, arguing instead how the 
US Food and Drug Administration (FDA) effectively curtailed research and therapy with 
psychedelics through evidentiary requirements that effectively disqualified the contextual and 
psychotherapeutic approach demanded by effective psychedelic therapy (Oram, 2018).  
The living room-like setting 
In today’s burgeoning clinical and research literature around psychedelic-assisted 
psychotherapy, the space for psychedelic drug use is commonly described as a “living room-like 
setting” (Johnson et al., 2008, pp.610-611), far from the sterile white-washed walls of a 
laboratory environment. Reference to the living room, as the communal room of a house, enfolds 
and naturalizes a particular, American bourgeois history. In the nineteenth century the front room 
of the family home was known as the ‘death room’, where deceased family members received 
their final respects. After a decline in mortality rates following the 1918 flu pandemic, the first 
World War, and improvements in public health, it was increasingly known as the ‘living room’, 
as first proposed by the esteemed Ladies Home Journal in 1910. Design-wise, Victorian mores 
were also being replaced by the idea that the room ought to reflect the personality of its designer. 
By the mid-twentieth century, seeking a comfortable, controlled and uninterrupted space for the 
therapeutic use of psychedelics, researchers often administered the drugs in their living rooms. 
Having worked with this wave of researchers, the senior therapist in the Johns Hopkins research 
team William (“Bill”) Richards explained to me, “when I designed the space at Hopkins, of 
course, I purchased similar furnishings, notably a long white couch, comfortable chairs for the 
therapists and soft lighting – all without sharp corners or breakable glass.”ii Over the past twenty 
years, the living room-like setting at Johns Hopkins has offered a model for psychedelic research 
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facilities at other universities. Use of the term ‘living room-like’ in psychedelic retreat centers, 
underground therapies, handbooks and guides has become a marker of competence when 
administering psychedelic therapy. 
When I was conducting my postdoctoral interviews, entering through one of the secure 
and soundproof doors to the Johns Hopkins living room-like session room complex felt to me 
like walking through a portal. Inside, a series of interconnected office rooms were carefully 
overhauled to have lamps with soft lighting, colorful paintings (including the German 
Expressionist Franz Marc’s Tirol (1914), which also hangs in Richards home study) adorning the 
walls, flowers, cushions and rugs with textures and patterns, bunting, a sofa with pillows and 
blankets for participants to lie on and a large bookshelf full of picturebooks on art and nature. 
Having passed through screening and preparation meetings and become familiar with the session 
room on prior visits, participants were invited to place photos of loved ones around the room, 
take their psilocybin pill from a ceremonial vessel, lie back on the sofa swaddled in a blanket 
with an eye mask on, and settle into carefully selected music comforted by the knowledge that 
their therapist-guides were ever-near. Suspended between the death of the body and the 
proverbial ‘death of the ego’, these living room-like settings are also closely monitored. A CCTV 
camera is hidden in plain sight, both recording a picture of ‘everything’ that happens in the room, 
while itself exceeding the container in its promise of data in the event that they are needed. The 
aesthetics of the camera, other monitoring equipment and the suspended ceilings characteristic of 
office buildings throw the eclectic curation of the space into relief: they reveal the nestedness of 
the session room within a broader scientific-bureacratic container, shaping participants’ own 
experiences through symbols of safety, accountability and rigor. 
Therapeutic containment 
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The different psychedelic substances are being paired with different therapeutic 
modalities in the development of particular drug-assisted therapies. One pole has been 
configured around the non-profit organization Multidisciplinary Association for Psychedelic 
Studies (MAPS)’ use of MDMA in the treatment of post-traumatic stress disorder, where 
participants are encouraged to re-enter their traumatic memories during the acute phase of 
MDMA ingestion. Another pole has been configured around the use of classic hallucinogens 
(and psilocybin in particular) in the treatment of a range of clinical targets, where participants are 
encouraged to ‘go inwards’ and follow their experiences wherever they lead, resisting the need to 
verbalize their experiences until after the session. Combined with the eclectic living room-like 
setting, a strong therapeutic alliance developed in the weeks preceding psychedelic sessions and 
the therapist teamiii remaining ever-vigilant towards the needs of the participant during their 
psychedelic session, participants can fully enter their psychedelic experiences, comfortable and 
unaware of the work being done by the therapists in maintaining the setting. 
Reflecting on the core of psychedelic therapy using psilocybin at Johns Hopkins, 
Matthew Johnson explained, “psychedelic experiences are about losing your shit!” Careful to 
note that he was referring to psychological and not physical responses, he continued, “In that 
sense, Leary was right when he said, ‘lose your mind’! It’s about reaching that point of 
criticality, letting it all explode – laugh like a madman, cry like a baby! You can do all this in the 
kind of safe space we create in the clinic.” Contained within research trial protocols, Johnson 
added, “this is something people who only do psychedelics recreationally sometimes don’t get” 
(personal communication). Therapeutically-speaking, emotions overflow and are re-contained. 
This occurs not only during but also after the psychedelic effects have worn off, requiring new 
spaces and modalities of expression. After the psychedelic session, writing is commonly 
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encouraged, as are artistic expressions and practices. Former participants have described to me 
reproducing aspects of the experiences afterwards, such as listening to the music playlists played 
during their session, or for participants of the smoking cessation study, inhaling the tincture 
given to them during their involvement as a reminder of their intention not to smoke – but also, 
and associatively, the content of their psychedelic experiences and the care they received. 
Pressures to standardize a formal ‘therapeutic model’ utilized in psychedelic therapy have 
grown over the last several years. One leading formalization has been the ACE (Accept, 
Connect, Embody) model recently developed by Rosalind Watts and colleagues at Imperial 
College London’s psychedelic research center (Watts and Luoma, 2019). In 2017, Watts’ team 
had found acceptance and connection as two themes that emerged through a thematic analysis of 
a twenty-person open-label trial using psilocybin to treat treatment-resistant depression. 
Consequently, their ACE model centers “accepting moment to moment somatic and emotional 
experience and opening up to what is painful”, and “connecting to the meaningful, beautiful, and 
the transcendent”, while embodiment is meant to reflect limitations in talk therapies, 
emphasizing instead “a whole body process of sensing and feeling” central to the therapeutic 
context  (ibid., p.97). The ACE model, as with the wider set of approaches derived from 
acceptance and commitment therapies, is developed around the normative goal of increasing 
‘psychological flexibility’, a term used to describe “the ability to contact the present moment 
more fully as a conscious human being and, based on what the situation affords, to change or 
persist in behavior in order to serve valued ends” (Luoma et al., 2019, p.94). At the growing 
interface of psychedelic psychiatry and cognitive neuroscience, such flexibility is understood to 
treat pathologies that derive from too-rigid prior expectations. In this way, today’s psychedelic 
therapeutics are being formulated as well-contained technologies of self-transformation.  
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Spiritual containment 
For the clinical researchers inspired by the religious and spiritual inflection given to 
psychedelics since the 1960s, the goal of these therapeutic protocols is not changes in one’s state 
of mind but, as renowned scholar of comparative religion Huston Smith commented in response 
to the landmark study of the psychedelic renaissance (Griffiths 2006; see epigraph), changes in 
one’s personality traits themselves. For this reason, when Katherine MacLean and colleagues at 
Johns Hopkins reported that increases in the personality trait of openness (considered one of the 
‘Big Five’ personality traits) were sustained for a year following psychedelic sessions (MacLean 
et al., 2011), their article was received with excitement and enthusiasm, seeding a growing 
research agenda to investigate psychedelic-assisted personality change. As I will suggest below, 
the role of diverse community-based initiatives proliferating around and in response to the 
clinical trials over the past ten years is downplayed by abiding discourses emphasizing the 
individualism of transformation through psychedelic psychotherapy treatment. 
Much research attention has been given to the subject-transforming power of mystical (or 
‘mystical-type’) experiences. The changes participants undergo as a result of participation in 
clinical trials are depicted through the imagery of ascending to the spiritual ‘mountaintop’, after 
which, “once you see you can’t unsee” (Narby, cited in Richards, 2016, p.33). This interpretive 
lens has been shaped by a distinctively American, pragmatist mysticism (Stace, 1960) that 
emphasizes the ‘fruits’ of the experience, and is Bill Richards’ preferred articulation. Another 
commonly articulated mechanism by which psychedelic therapy is claimed to work, found in 
both the research and therapy literatures, is that it is nondirective, rather activating one’s ‘inner 
healer’, generating less what one wants to experience and more what one needs to experience. 
While such configurations of the spiritual can be contrasted with traditions of working with 
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psychedelic substances outside of the Euro-American modern (for example, Gow, 2001) and in 
underground sites adjacent to the university clinics themselves (Davis, 2019), it serves a crucial 
contextualizing purpose in the development of psychedelic psychiatry. For the long-standing 
image of precision medicine of ‘magic bullets’ which target and reverse in precise ways known 
pathogenic substances or mechanisms, the notion of the inner healer promises an extreme form 
of precision medicine, personalized down to the idiosyncratic singularity of each individual.iv As 
a narrative framework providing a script for experiences that in turn secure the felt reality of 
such narratives, the ‘inner healer’ operates discursively to contain powerful psychedelic 
experiences. Together with the centrality of trust in the preparation of psychedelic sessions and 
the long-recognized suggestibility of psychedelic experiences, it supplies the emerging 
knowledge base of psychedelic psychiatry with social and spiritual frameworks in the 
development of therapeutic protocols and understandings of mechanisms of change. 
The use of the living room-like setting, the standardization of therapeutic modalities and 
the popularizing of particular spiritual discourses are articulated through and alongside the need 
to attend to the set and setting of psychedelic use. They are producing knowledge about what 
psychedelics in particular contexts do, whose limits in turn can be used to signal the limits of 
such knowledge. Indeed, as we shall see in the following section, these epistemic and therapeutic 
contexts are braided with the particular politics of the psychedelic renaissance. 
Medicalization as Containment 
Bob Jesse’s language of containment resonates with a wider framing in the psychedelic 
community of the work of set and setting as about building appropriate containers for 
psychedelic use. As medical intervention, the aspiration to successfully contain psychedelic 
experiences evokes precision, resonating with similar imperatives in relation to disease 
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epidemics (Cohen, 2011) and nuclear waste (Freeman, 2019). In embracing the language of ‘set 
and setting’ as part of a strategic distancing from the tumult of the ‘psychedelic sixties’, 
medicalizing discourses seeking to re-legitimize psychedelic therapy are successfully braiding 
epistemic and therapeutic imperatives with political and economic ones. Some university-based 
psychedelic researchers have sought to dissuade, if not outright criticize, use beyond controlled, 
sanctioned environments such as the clinical trials themselves. A deeply-held concern amongst 
these university-based labs has been that the drugs will not be confined to particular sets and 
settings – that ‘irresponsible’ (usually code for ‘recreational’) use will take off, leading to 
another political backlash. A related concern amongst some psychedelic scientists is a 
‘boomerang effect’ whereby the recent successes of research trials will provoke a doubling down 
of negative prejudices regarding psychedelics. Generally, researchers have sought to avoid the 
political debates, keenly not wanting what many describe as “another Leary” (see also Giffort, 
2020). An exception that proves the rule in the research in peer-reviewed journals was Nour et 
al. (2017), where the authors drew on data from an anonymous survey to conclude that measures 
of psychedelic-induced ‘ego dissolution’ positively predicted liberal political views and 
negatively predicted authoritarian political views. This caused a stir in the wider psychedelic 
community, which had grown accustomed to psychedelic scientists resisting invitations to wade 
into the ‘political’ debates through their research (and prompting ‘correctives’ from psychedelic 
researchers – for example, see Johnson and Yaden, 2020). By contrast, their hope has been that 
the clinical trials are able to continue through controlled and legal research settings, untroubled 
by reports of surging community-based use or adverse effects until such time as the trials yield 
enough data to warrant the rescheduling of the compounds and licensing of their use. Indeed, 
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many psychedelic researchers and therapists attribute such adverse effects precisely to having 
had a poor set and setting. 
The clinical trials designs are intended to develop reimbursable, targeted and contained 
interventions that can be enrolled into healthcare systems once – it is assumed – their efficacy 
and safety is sufficiently evidenced in the near future. As chairman of the board of the 
Multidisciplinary Association for Psychedelic Studies (MAPS) John Gilmore put it to the 
Burning Man audience at Palenque Norte in 2013, “It’s not really science…it’s jumping through 
hoops” (Gilmore, 2013). For those in the psychedelic community invested in psychiatry, having 
the appropriate governing and regulating bodies recognize the importance of suitable settings for 
the therapeutic use of psychedelics inspires a secondary hope, that the care over establishing safe 
and efficacious containers in emerging paradigms of psychedelic medicine will offer templates 
for a much more contextually-sensitive psychiatry in general. This hope contains a redemptive 
promise, to rectify psychiatry’s over-embrace of acontextual drug-based remedies since the mid-
twentieth century neurochemical turn. 
The aspirations to medicalize often sat uneasily in the wider communities of psychedelics 
users and advocates who were present at the conferences, workshops and informational tents at 
festivals I attended during my fieldwork. Many simply wanted to be able to use psychedelics 
without sanction, supporting grassroots decriminalization and legalization initiatives that have 
begun to grow apace across the US. Such actors embrace positions that themselves are in tension 
with one another, including the libertarian call for the right to ‘cognitive liberty’, and social 
justice commitments to a politics of mutuality and intersectionality and cultural transformation. 
The standard response from advocates of overground research and therapy has been that 
medicalization is the thin end of the wedge, foreshadowing wider accessibility. Yet attempts at 
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concerted action within the psychedelic community to agree on the details of how psychedelics 
will be made available once rescheduled have been fractious. Conference gatherings have been 
the sites of heated disagreement. With the recent entry of venture capital and for-profit start-ups 
into the psychedelics space, the tensions between the varied politics of medicalization, 
decriminalization and legalization amongst scientific, underground, religious, shamanic and 
indigenous communities has ratcheted up considerably (Noorani, 2020). 
These psychedelic politics can be contrasted with those of the first wave of laboratory 
and clinical research and therapy in the 1950s and 1960s, then primarily with LSD. By the 
1960s, elitist programmatics epitomized by the collaboration of literary figure Aldous Huxley 
and psychiatrist and psychedelic researcher Humphry Osmond (see Bisbee et al., 2018) argued 
that, at least at first, psychedelics should be reserved for the carefully-selected intellectually 
curious and aesthetically refined few, while populists such as Timothy Leary came to celebrate 
widespread use, reveling in the very uncontainability of psychedelic experiences. Both 
emphasized perennial forms of psychedelic mysticism marked by psychedelic-induced 
‘consciousness expansion’ that was unbounded, opening into spatio-temporal infinity, what 
Huxley (1954) coined the ‘Mind at Large’. These ideas undergirded the optimism that 
psychedelics could usher in a new age. Drug prohibitionists in the Nixon administration called 
on experts who claimed that psychedelics were producing psychotic-like states, claims opposed 
by those who suggested negative psychedelic experiences such as terror, ego-inflation and 
grandiosity only resulted from a poor set and setting and thus do not justify the prohibition of the 
substances themselves. 
Today’s medicalization-oriented researchers reflexively utilize these critiques as 
justification for new economic models of containment, simultaneously solving the problem of 
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patents on psychedelic compounds being either expired or difficult to obtain. If psychedelics are 
only becoming known to us for what they do under particular set-and-settings, these 
medicalization advocates reason, only the protocols and settings that have been used to generate 
the controlled scientific knowledge of them are the ones that can and should be condoned. This 
provides a rationale for commodifying not the drugs per se but whole therapeutic protocols. One 
legal mechanism for this is through the creation of what the FDA call a ‘bifurcated schedule’, 
whereby drugs developed and sold as larger commodities are placed in a less severe legal 
category than the drugs in their uncommodified form (see Noorani, 2020, pp.37-38). As such, 
reliance on set and setting enables psychedelic psychiatry to embrace the historic failures of drug 
research to accommodate context. This in turn requires new training systems to be put in place 
for those who want to train to be psychedelic therapists in the near future, a current opportunity 
for drug sponsors and educational centers seeking to position themselves at the vanguard for 
when overground psychedelic therapy is legalized. Ideas of ‘set and setting’ which had been 
developed as ways to support experiences of unboundedness are returning today as the 
precondition of economic viability. In turn, political and economic imperatives to contain 
psychedelic use provide additional constraints for their epistemic and therapeutic containment. 
The challenge of containment for psychedelic science today, then, moves seamlessly 
between the need to contain psychedelic experiences and put the experiences to use in 
therapeutic ways, and the need to contain the substances themselves within legal spaces of 
research and approved therapy. In the following two sections I draw on the preceding analysis of 
the braided nature of the epistemics, therapeutics and politics of contemporary psychedelic 
research and therapy to think through some of the work of containment. First I suggest that, 
despite intentions to the contrary, clinically-produced psychedelic experiences commonly escape 
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their containment within the individuals to whom the therapy is administered. I then consider 
what practices of containment reveal about the properties of the psychedelic container, proposing 
that we view this as recapitulated in the cultural politics of psychedelia. 
Leaks and Overflows 
Ethnographic data reveals how attempts at restricting psychedelic experiences to the 
settings of university-based clinical trials is failing in the very unfolding of the research, stoking 
yet further anxieties about psychedelic containment. Consistent with material analyses of 
containers (Shryock & Smail, 2018), I suggest the sheer immensity of the experiences produced 
is creating its own overflows in at least four ways. Firstly, the vivid and proselytizing accounts of 
former participants, who since became advocates for the therapy they received. Jesse’s address to 
the psychedelic community at the Horizons conference in 2016 spoke to a kind of quiet 
conversion work, which he advised the audience should be about ‘attraction not promotion’, 
evoking the eleventh tradition of Alcoholics Anonymous. But even as Jesse was speaking, such 
accounts had begun to snowball, and today they saturate the media landscape around alternative 
and holistic medicine and promising new avenues for psychiatry.v  
The media attention has been a double-edged sword for psychedelic researchers, on the 
one hand leading to increased research funding and receptivity across many publics for 
psychedelic research, while on the other hand, threatening to negatively affect the efficacy of the 
clinical trial treatments by complicating enrollment and confounding the results of trials 
currently underway. These looping effects are particularly large in the case of psychedelic drugs 
because of their sensitivity to set and setting. This raises questions about cohort effects, the 
changing nature of participants’ expectations, and the lack of study of ‘disappointment effects’ in 
relation to these ever-more-exciting therapeutics. 
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Secondly, during the past decade, clinical trial research has also fed into, galvanized and 
in turn benefitted from the formation of community-based ‘psychedelic societies’. The first US-
based psychedelic society on record was started by Daniel Jabbour in San Francisco in 2011 
who, in penning an article for the MAPS’ newsletter in 2014, drew on a common trope in the 
psychedelic community aligning psychedelic and sexual orientation politics in his call for readers 
to set up more psychedelic societies: 
“If you decide to come out of the psychedelic closet: Be yourself, be educated, and talk 
about your own experience as much as you can. It doesn’t hurt to point out that FDA-approved 
clinical research is taking place with multiple psychedelics” (Jabbour, 2014, p.36).  
Six years later, an online resource at the time of writing lists 168 psychedelic societies 
across 36 countries, with the large majority in the US, followed by Canada and the UK. Events at 
psychedelic societies I have attended ranged from anarchist to hierarchical and professionalized. 
They convened in cafes, bars, community centers and – in rare cases – their own designated 
spaces, and many have continued online in the COVID-19 era. Activities include hearing 
speakers ranging from university researchers to local foragers and botanists, watching movies 
and documentaries, sharing psychedelic experiences and debating the future landscape of 
psychedelic drugs and plant medicines. More psychedelically-naive attendees come with 
anxieties about their imminent trips to the ‘rainforest’ or Amsterdam, referencing places where 
the use of psychedelic substances is legal. Amongst my interlocutors, other reasons for such 
travel include for “spiritual exploration” and existential crises. Some former trial participants 
came to their local psychedelic societies in search of community. Indeed, one of Johns Hopkins’ 
lead therapists Mary Cosimano, who has guided sessions with Richards since Johns Hopkins’ 
psychedelic research trials began in 2001, describes actively signposting participants to 
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psychedelic societies as places to find community and keep integrating their experiences. 
Today’s eight activist-organizers at the center of the Baltimore Psychedelic Society (BPS) 
include two former trial participants. 
Thirdly, psychedelic experiences in the context of clinical therapeutics also generate deep 
connections between participants and their study teams, in particular with their therapist-guides. 
These connections, often attributed therapeutic potency in themselves in the clinical research 
literature, fed friendships and wider community networks around the research trials. On the eve 
of the summer solstice in 2013, lead-author of the 2011 openness study at Johns Hopkins, 
Katherine Maclean, joined with experimental musician, psychonaut, and former trial participant 
Twig Harper, and (now-defunct) local newspaper Baltimore City Paper contributor and ‘magical 
thinker’ Michael Hughes, to inaugurate the It Is group, described in their email publicity as “a 
salon in the spirit of American mysticism” hosted at Tarantula Hill, Harper’s West Baltimore 
home. This was an early example of a gathering intended for the sharing of psychedelic 
experiences people had had both inside and outside of Johns Hopkins’ research trials. In other 
cases, the distance between university research and illicit community-based use was carefully 
managed, such as when in 2017 a Johns Hopkins psychedelics researcher agreed to help the BPS 
devise the format and guidelines of regular integration group sessions only on condition of 
anonymity. 
The precursor to BPS was formed in early 2015 by Mike Margolies. After a 
2012 ayahuasca experience in Peru, Margolies "dropped out of corporate America” the following 
year and spent 15 months backpacking and living in India and Southeast Asia. He then moved to 
Baltimore to be near his family. Not wanting to return to his prior career, Margolies felt 
compelled to commit to psychedelic advocacy and began organizing local meet-ups. After an 
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initial flurry of meetings with guest speakers including from the local research team at Johns 
Hopkins, Margolies expanded his work in psychedelic education and community building more 
globally, including helping to set up psychedelic societies elsewhere. The local group 
transitioned its identity to the BPS in 2017 as others took up organizing roles. One of these 
activist-organizers described to me the crucial role of the community integration sessions devised 
by the above-mentioned anonymous Johns Hopkins researcher in re-energizing the society. 
Today the BPS takes part in the broader local networks of queer and anti-racist activity. The BPS 
is actively involved in local and state-wide harm reduction initiatives, denouncing the 
‘psychedelic exceptionalism’ that divorces the popularizing and mainstreaming of psychedelic 
drugs from a broader cross-drug program of policy reform and overdose prevention. 
Fourthly, those whose primary work has been as clinical trial researchers, therapists and 
guides often deeply believe in the intrinsic value of carefully-contained psychedelic experiences, 
contrasted with many of their professional interlocutors, including drug regulators and the 
growing number of industry sponsors, whose priorities more often lie in regulatory innovation 
and medicalization. Many are engaging in activities and creating new forms of value in 
community-based projects to the side of their primary work. These include setting up non-profit 
and charitable organizations to offer signposting and distill best practices from across 
community-based and clinical work, and working in harm reduction, for example volunteering at 
festivals where psychedelics are being used. Maclean left her tenure-track position, and co-
founded The Psychedelic Education and Continuing Care Program in New York in 2015, 
profiled at the 2016 Horizons conference for its pioneering community integration group model. 
Maclean described the model as a “ripple” outwards from the specific support structures devised 
at Johns Hopkins by Cosimano for participants in the ‘high support’ arm of a research study 
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administering the psychedelic psilocybin to spiritual practitioners between 2009 and 2013. Today 
psychedelic integration groups have been set up across the US and beyond (though largely in the 
UK), where participants from clinical trials, psychedelic drug tourists and illicit underground 
psychedelic users come together and discuss intense psychedelic experiences, what they have 
come to mean and their subsequent impact. 
In 2015-2016, I found conversations in the BPS meetings I attended very oriented around 
the Johns Hopkins clinical trials research. When I was invited to speak in the summer of 2015 
about my research then-underway at the university, I met people who had participated in other 
such research trials. Speaking from the audience, one well-known psychonaut and former 
participant put it concisely, “People get really unspun at Hopkins – then they don’t know what to 
do!” I came to learn that there were many Baltimoreans who knew each other either before or 
since taking part in Johns Hopkins studies. The university had been sourcing participants from a 
local community that was already loosely knit together. Despite posturing to the contrary, the 
clinical research team was not separate from underground communities of psychonauts. The 
staged separation between the legal overground trials and underground activity is put in question 
by the ways the research trials – which made Baltimore the pre-eminent city on the ‘psychedelic 
renaissance’ map – help consolidate underground relationships and communities further. It had 
led some local Psychonauts who held to an antagonistic relationship between underground and 
overground use of psychedelics to suggest they need to pick up the pieces once overground trials 
end. With the need for participants inflaming and sanctioning a collectivized underground of 
psychonauts, being seen by the regulatory and legal authorities to be containing psychedelic use 
has proven to be work. 
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While psychedelic researchers have articulated the need to work within the constraints 
provided by the current regulatory systems to quietly – and without any serious adverse effects – 
demonstrate that psychedelic experiences have great worth, the research program in practice has 
shaped much of its local environments, in the form of extra-clinical activity, ongoing modes of 
integration support, and psychedelic societies where researchers and therapists, former 
participants develop new socialities with a host of other psychedelic aficionados. As much bio- 
and chemo-socialities (Shapiro and Kirksey, 2017) as they are new biomedical borderlands, the 
leaks and overflows from the constraints of particular set and settings index different failures in 
attempts to determine ‘drug effects’. It could conversely be interpreted to show how the so-called 
‘psychoactivity’, life-altering capacities or potential for healing of contemporary psychedelic-
assisted psychotherapies resides in the wider milieu, destabilizing the claim of the randomized 
controlled trial methodology to locate efficacy within the substances themselves. 
Protection and Reflection 
The boundaries that are rhetorically and materially erected and maintained around the set 
and setting of clinical research in the psychedelic renaissance also shape particular qualities of 
the container. Firstly, through my ethnography I have come to think of participants’ experiences 
in overground psychedelic research trials as constituted not only through invitations, but through 
exclusions and refusals that work to protect the spaces thereby contained. At Johns Hopkins 
participants are asked to take off their shoes and turn off their phones. The space offers no 
indication of the time, which instead is bookended by their arrival into the care of their two 
session therapists, and being picked up six to eight hours later by a pre-designated friend or 
family member. Participants are made fully aware that consumption of an otherwise-illegal drug 
is not illegal in the clinical trial’s zone of exception. On dosing days participants get to leave the 
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hum-drum of daily concerns at the threshold to the session room. While much of the media 
discourse around psychedelics refers to the breaking down of walls and a celebration of 
interconnection, we might note the paradox that this only occurred through an ethic of exclusion 
made possible by the establishing and active maintenance of the setting’s own walls. 
The standard interpretation of the value of psychedelic experiences has been in terms of 
entry into a larger world. Coining the term ‘psychedelic’ in reference to their supposed ‘mind-
manifesting’ nature, Osmond insisted that they are “not escapes from but enlargements, 
burgeoning of reality” (1957, p.428), an idea which continues to be cited in the recent revival of 
scientific research. Yet the protective properties of the set and setting are suggestive instead of a 
centripetal value in the therapeutic modality, creating spaces protected from the stress and 
distress of everyday life. This includes demands on attention and labor and toxic environments. It 
enables participants to be vulnerable and receptive to their experiences on the sofa. These 
demands, including upon others in participants’ lives, allowing one to can get away from it all in 
order to get ‘into’ it all, may contribute to the significant overrepresentation of White 
participants being enrolled into psychedelic science trials (Michaels et al., 2018). Recently-
voiced critiques within the psychedelic community have argued that psychedelic science is 
mostly benefitting normative, privileged populations, while using these bodies to make universal 
claims about the action of psychedelics on the human body in general, echoing broader social 
scientific concerns with skewed knowledge production (Henrich et al., 2010). A recognition of 
the attention and labor required to sufficiently protect these spaces for psychedelic experiences 
helps explain the magnitude of the betrayal felt, individually and collectively in the psychedelic 
community, when reports have surfaced of breaches in the duty of care, in particular in relation 
to cases of sexual harm (see for example Buisson, 2016). 
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Secondly, the set and setting reflects the self even as it shapes it. The reflective function 
of the container echoes the very etymology of the psychedelic experience, that a priori ‘it’ is 
contained within ‘us’, mind-as-manifestable. In the clinical research sites, practices of mirroring 
take on an important role, encouraging curiosity through reflecting back to the participants what 
they communicate. A technique used in psychedelic research at Spring Grove hospital in 
Maryland in the 1960s and 1970s was to offer participants a handheld mirror at especially 
charged moments during a session for participants to literally encounter their own reflection. 
Cosimano explains that the mirror was used regularly when the Johns Hopkins trials started in 
2000, was used less once new therapist-guides came on board and today is used sparingly. That 
the need to contain the other is connected to the fact that ‘we’ already contain ‘them’ is not 
particular to psychedelics. Yet, as has been pointed out in relation to fantasies of viral 
containment (Cohen, 2011), this formulation occludes as much as it reveals. For instance, who 
claims that psychedelics are reflecting us back to us, what notion of ‘us’ is this, and what labor 
must go into the building and maintaining of containers that enable us to be alone with 
ourselves?  
It is important to recognize the collective and feminized aspects of the infrastructural 
work. Shorthall (2014) attends to this in relation to the use of psychedelics in the US 1960s 
counterculture. Regarding the ‘us’ in question, the psychedelic mysticism operative in 
contemporary psychedelic science is highly prizing a ‘unitive’ consciousness that has sublimated 
the dualism of self and other (Stace, 1960; Griffiths et al., 2006). This model of the psychedelic 
self resonates with Jungian approaches common across psychedelic therapy, organized around 
the fully integrated psyche achieved through individuation. Literature produced in a more 
neuroscientific lexicon posits that under psychedelics, the self is able to experience itself 
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directly, not through the other, nor (a possibly pathogenic) self-consciousness. According to the 
most common trope to emerge from the neuroscientific literature in recent years, this self-
consciousness has been tied to the activity of the human brain’s default mode network, whose 
identification as the ‘seat of the ego’ has been celebrated in the coverage of psychedelic science. 
This includes in bold statements made by Amanda Feilding, Countess of Wemyss and March, 
and founder of the Beckley Foundation, the pre-eminent UK charity funding psychedelic 
research and calling for drug policy reform, who noted at the large Psychedelic Science 
gathering in Oakland, California in 2017 that her own grandparents were family friends with 
William James and Aldous Huxley. Combining computational and psychoanalytic registers, 
prominent psychedelic researcher Robin Carhart-Harris and neuroscientist Karl Friston recently 
argued that the ego be more accurately understood as the highest level of extant predictions the 
brain-as-modeler has about the world. By loosening this level of predictions through the 
deactivation of the default mode network, psychedelics allow a more expansive self to manifest 
(Carhart-Harris and Friston, 2019). Huxley’s ‘Mind at Large’ returns as an individualized ‘brain-
at-large’. 
Other notions of the self circulating in psychedelic therapeutics are deeply peopled with 
others, consistent with the wider literature on the default mode network that suggests it is central 
for how we think about others, theory of mind and the ‘narrative self’ (Spreng and Hanna, 2015). 
Such peopled minds have more in common with what Davis (2020) has recently called a 
pessimistic gnosis, which he argues is alive and well in the psychedelic underground. Dialectical 
models of self (re)produced through the gaze of others may better account for the experiences of 
non-normative participants coming into the clinical trials. In reaction to the disproportionate 
whiteness of demographics of psychedelic trial participants, in 2018 MAPS hired Monnica 
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Williams, an African American clinical psychologist and specialist in racial trauma as Principal 
Investigator of the Connecticut site of their open-label phase II clinical trials studying MDMA-
assisted psychotherapy in the treatment of post-traumatic stress disorder. Williams’ team brought 
a racial trauma lens to understanding the experiences and pathologies of trial participants, and 
her team sought to adapt the study protocol in ‘culturally sensitive’ ways. The site closed early 
for myriad reasons including structural racism and sexism (Williams et al., 2020). While perhaps 
unsurprising given systemic inequalities, what this reveals is how the racial and gender politics 
of the contemporary psychedelic revival can be traced through the kinds of self that psychedelic 
experiences are purported to reflect back.vi 
Deriving from con meaning ‘altogether’ and tenere meaning ‘to hold’, the word container 
is itself a container, holding together its parts to form the meaning of ‘hold-together’. Such 
holding together is one way of articulating the value of interconnectedness, commonly espoused 
as a key insight of psychedelic experiences within the psychedelic community. A more 
polysemic engagement with practices of container-making thus offers to complicate the 
psychedelic discourse celebrating interconnection. Indeed, practices of protection and of 
reflection recapitulate two jostling cultural politics of safe spaces within the psychedelic 
community: calling out or ‘cancel’ culture and transformative justice. In relation to calling out, 
naming and organizing against sexual harm, patriarchy and White supremacy has risen up in the 
psychedelic movement, crystalizing around the White cis-male guru or cult leader. There has 
been a growth of spaces that are necessarily exclusive, enabling a safety premised on that 
protectedness, including non-White, people of color-led, women-only and women-led 
psychedelic events and groups.vii There has also been a growth of practices of transformative and 
restorative justice, calling in perpetrators for accountability, reflection and self-refashioning. It is 
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not the case that calling out and transformative justice are aligned with protection and reflection 
respectively. For instance, calling out has operated through the (perhaps unrecognizable) images 
of ‘us’ reflected back to us, while transformative politics requires a degree of exclusion in order 
for transformation to occur, just as the walls of the crucible afford transformative heat and 
pressure. 
Conclusion 
Today’s psychedelic experiences produce inspiration, enthusiasm, compulsions to 
understand and master, new forms of messianism and more. As politically, epistemically and 
therapeutically useful, the term ‘set and setting’ in psychedelic science presents a knot of 
collisions, enabling it to do the work of policing where psychedelics are and should be used, 
while articulating anxieties about containment at different scales. It is a historical question to 
what extent the uncontainability of psychedelic experiences itself arises from their history of 
associationsviii with societal breakdown and madness, making their containment especially 
pressing today. What the preceding analysis reveals is that today’s professionalizing and 
medicalizing drive within psychedelic therapeutics and the social justice-oriented cultures often 
opposed to it both partake of a turn away from the emphasis on the unboundedness of the 
mystical as articulated by Huxley, Leary and others. Even the interest in the mystical experience 
as a mechanism of change in the therapeutic use of psychedelics is only insofar as it bears fruit in 
the form of long-term self-transformation. For mysticism to play any role in today’s psychedelic 
renaissance, it can no longer remain unbounded. 
Through insistence on instating and managing the proper set and setting, psychedelic 
containers can be analyzed in terms of how they leak and overflow, protect and reflect. 
Proliferating lists and discussions on the work of ‘integration’ suggest the value of today’s 
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therapeutic psychedelic experiences lies as much in the endurance of the ‘abiding light’ of an 
experience as its initial cultivation. And yet, indexed in the growth of local integration services, 
community-based integration work is rendered invisible by measuring apparatuses which are 
designed around the imperatives of the randomized controlled trial and do not probe such 
dynamics. Huston Smith’s provocative question to the psychedelic research scientists serving as 
an epigraph remains unanswered. At the same time, the shifting histories underlying the debates 
around set and setting invite the question of whether all practices of containment entail particular 
ways of seeing ourselves and protecting ourselves. Whether limited to psychedelics or more 
broadly, the political and ethical stakes lie in the possibilities opened up by considering practices 
aimed at protecting spaces as, at the same time, material and relational crafts for cultivating and 
proliferating modes of reflection. 
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